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Abstract
The literature concerning the subcellular location of Y-box binding protein 1 (YB-1), its abundance in normal and cancer
tissues, and its prognostic significance is replete with inconsistencies. An explanation for this could be due in part to the use
of different antibodies in immunohistochemical and immunofluorescent labeling of cells and tissues. The inconsistencies
could also be due to poor resolution of immunohistochemical data. We analyzed two cohorts of breast tumours for both
abundance and subcellular location of YB-1 using three different antibodies; two targeting N-terminal epitopes (AB-a and
AB-b) and another (AB-c) targeting a C-terminal epitope. We also investigated stress-induced nuclear translocation of YB-1 in
cell culture. We report that both AB-a and AB-c detected increased YB-1 in the cytoplasm of high-grade breast cancers, and
in those lacking estrogen and progesterone receptors; however the amount of YB-1 detected by AB-a in these cancers is
significantly greater than that detected by AB-c. We confirm our previously published findings that AB-b is also detecting
hnRNP A1, and cannot therefore be used to reliably detect YB-1 by immunohistochemistry. We also report that AB-a
detected nuclear YB-1 in some tumour tissues and stress treated cells, whereas AB-c did not. To understand this, cancer cell
lines were analyzed using native gel electrophoresis, which revealed that the antibodies detect different complexes in which
YB-1 is a component. Our data suggest that different YB-1 antibodies show different staining patterns that are determined
by the accessibility of epitopes, and this depends on the nature of the YB-1 complexes. It is important therefore to
standardize the protocols if YB-1 is to be used reproducibly as a prognostic guide for different cancers.
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Introduction
Y-box binding protein-1 (YB-1, P67809) is a member of the
cold-shock superfamily and plays a role in multiple biological
processes including cell proliferation, DNA repair, translation and
transcription (reviewed in [1,2,3]). Despite being able to function
as a transcription factor, .90% of YB-1 is located in the cytoplasm
[1] where it binds RNA and regulates translation [4,5]. Nuclear
translocation of YB-1 has been reported to occur during the G1 to
S phase transition of the cell cycle [6] and in response to a range of
stressors including ultraviolet (UV) radiation [7,8] and DNA
damaging agents, such as cisplatin [8,9] and mitomycin C [10]. As
tumour cells are thought to be under constant stress due to
sequential mutations, the significance of nuclear YB-1 in cancer
has been the focus of ongoing investigation.
Early immunohistochemical observations showed that YB-1
protein is elevated in ,75% of breast cancers [11]. This was
subsequently extended to a wide range of common human
cancers, including cancers of the prostate [12], lung [13], skin
[14], bone [15], and others [16,17,18]. However, there is
disagreement as to whether nuclear YB-1 is a significant
prognostic factor and there are discrepancies in the literature as
to whether YB-1 is present in normal tissues. For example,
immunohistochemical studies report an absence of YB-1 staining
in normal breast tissue [19] and melanocytes [14] but clear
evidence of both nuclear and cytoplasmic staining in tumour
tissues with elevated levels of both being associated with tumour
progression. Increased nuclear YB-1 has also been reported to
correlate with lymph node metastasis in patients with non-small
cell carcinoma [20], but this correlation was not reported by others
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20603[13]. Nuclear YB-1 staining has also been associated with
increased expression of multidrug resistance 1 (MDR1) in patients
with poor prognosis [11,21]. In other reports, increased cytoplas-
mic YB-1 was associated with poor patient prognosis where
nuclear YB-1 was rarely detected (in ,2% of tumours) [22].
One possible explanation for these differential immunostaining
patterns is that the antibodies used in the above studies have
different immunoreactive properties. The majority of antibodies
used in these studies are generated to either residues within epitope
a (Figure 1) [11,19,21], or to residues 299–313 within epitope c
[12,13,18,22,23,24] and are polyclonal antibodies raised in rabbit
resulting in an inherent variability in immunoreactivity. If true, the
prognostic significance of YB-1 immunostaining would therefore
be highly antibody dependent and such variations would make the
development of an YB-1 based prognostic marker difficult.
To test this hypothesis, we examined two breast cancer cohorts
with 3 antibodies whose epitopes are identified in Figure 1. Our
studies show that AB-b is of little prognostic value overall, due to
cross-reactivity with hnRNP A1 [25]. On the other hand AB-a and
AB-c both have significant prognostic value, as their immunoreac-
tivities correlated with both increasing grade and the absence of
estrogen and progesterone receptors (ER/PR negative). However
AB-a appeared to be more sensitive at detecting a prognostic
association. We also found that AB-a detected nuclear YB-1, while
AB-c d i dn o t ,b o t hi nt u m o u r sa n di nc e l l st r e a t e dw i t hU Va n d
cisplatin. We propose that this differential immunoreactivity is due to
protein-protein interactions rendering the epitope required for AB-c
binding unavailable. Our findings bear relevance to the numerous
studies that aim to establish YB-1 as a prognostic indicator and may
impact on the development of a YB-1 based prognostic screen.
Materials and Methods
Clinical samples
Breast cancer biopsies from Dunedin Public Hospital, New
Zealand, obtained prior to treatment, (n=90; Table 1) were
examined. Normal breast tissue was obtained from 10 reduction
mammoplasties, together with normal adjacent tissue ($10 mm
from the malignant tissue). Additionally, two separate tissue
microarrays (TMAs) were obtained from the Singapore General
Hospital (n=206, Table 2).
Ethics statement
Written consent for samples used in the New Zealand cohort
was obtained from patients and the use of these samples was
approved by the Otago Ethics Committee, Ministry of Health,
New Zealand Government, CPD 02/01 and also by the Multi-
region Ethics Committee, Ministry of Health, New Zealand
Government, MEC/07/05/065. Written consent for the Singa-
pore TMAs was obtained from patients and use of the material
was approved by the Institutional Review Board of the Singapore
General Hospital.
Antibodies
Three rabbit polyclonal antibodies were used in this study.
AB-a was affinity purified using the immunizing peptide MSSE-
AETQQPPA, as previously described [16,25]. AB-c was affinity
purified using the immunizing peptide CDGKETKAADPPAENS
(residues 299–313, epitope c, Figure 1, as previously described
Figure 1. Linear representation of YB-1. YB-1 contains a highly conserved cold shock domain (CSD); a nuclear localization signal (NLS); a
cytoplasmic retention signal (CRS); red bars indicate the epitopes (a–c) for YB-1 antibodies.
doi:10.1371/journal.pone.0020603.g001
Table 1. Clinical and Pathological Characteristics of the NZ
Cohort.
Number of patients 90
Median age (range) (years) 58 (28–86)
Pathological stage at diagnosis
Stage 1 13
Stage 2 67
Stage 3 10
24 month survival (%)
Stage 1 100
Stage 2 91
Stage 3 61
Histological type [n (%)]
Ductal 83 (82)
Lobular 6 (7)
Tubular 1 (1)
Histological grade [n (%)]
Grade 1 32 (35)
Grade 2 32 (35)
Grade 3 28 (30)
Lymph node status [n (%)]
Negative 40 (44)
Positive 50 (56)
Estrogen Receptor status [n (%)]
Negative 22 (24)
Positive 68 (76)
Progesterone Receptor status [n (%)]
Negative 39 (43)
Positive 51 (57)
Subtype [n (%)]
Luminal 72 (80)
Luminal A 49 (54)
Basal-like 8 (9)
Her2+ 10 (11)
doi:10.1371/journal.pone.0020603.t001
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containing the YB-1 peptide conjugated to Thiopropyl-Sepharose
6B gel (column prepared by Mimotopes). AB-b is a commercially
available antibody (Abcam ab12148) targeting residues 23–52
(Figure 1, epitope b). A mouse monoclonal to hnRNP A1 (Abcam,
ab5832, clone 9H10,) antibody was used in the immunofluores-
cence experiments. The b-tubulin mouse monoclonal antibody
(E7) used as a loading control in Western blotting was obtained
from the Developmental Studies Hybridoma Bank (DSHB), Iowa.
Immunohistochemistry (IHC)
Sections fixed in neutral-buffered-formalin and embedded in
paraffin wax were processed using a standard citrate buffer antigen-
retrieval protocol. Three rabbit polyclonal primary antibodies were
used to detect YB-1, (see above). These were diluted in 1%BSA in
PBS as follows: AB-a; 1:1200, AB-b; 1:4000, AB-c; 1:1000 and
incubated overnight at 4uC. Detection of the primary antibody
carried out using the EnVision
TM+ Dual Link system (Dako)
according to the manufacturer’s protocol. Specimens were
counterstained in Gills haematoxylin and mounted in Entellan
(ProSciTech). Staining pattern and intensity was visualized using a
Zeiss Axioplan compound microscope, and photographed with a
SPOT-RT CCD camera (Diagnostic Instruments).
Immunohistochemistry Assessment
100 cells in each specimen were scored according to the
presence and intensity of staining. Negative staining was scored as
zero, weak as one, moderate as two and strong as three. The
intensity of staining within the tumour was compared to at least
three regions of adjacent normal tissue, as shown in the insets of
Figure 2. Identification and assessment of immunohistochemical
staining of diagnostic breast tissue was carried out in consultation
with registered pathologists.
Cells and cell culture
Established cell lines A549, MCF-7, and T47D were obtained
from the CMRI cell line repository and were validated for
authenticity by CellBank Australia using short-tandem-repeat
profiling. A549 cells were cultured at 37uC, 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen)
supplemented with 10% v/v fetal bovine serum (FBS). The breast
cancer cell lines MCF-7 and T47D were cultured at 37uC, 10%
CO2 in DMEM without phenol red (Invitrogen) supplemented
with 10% v/v FBS and insulin (Sigma, 10 mg/ml). Primary cell
lines were related back to original donor tissues. IIICF/c, Fre16
and melanocytes were cultured at 37uC, 5% CO2 in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Invitrogen) supplemented
with 10% v/v fetal bovine serum (FBS, JRH). Bre56 and Kre36
cells were cultured in MCDB 170 medium (Invitrogen) and
defined keratinocyte-serum free medium (Invitrogen) respectively.
Both were grown at 37uC, 5% CO2.
Cell stress treatment
Cells (2610
4 cells per well) were seeded into chamber slides,
treated as indicated, and incubated at 37uC for 24 h. Cisplatin
(Sigma P4394) was prepared just before use as a stock solution in
DMSO at a concentration of 10 mM (10006working concentra-
tion). Cells were treated with 10 mM cisplatin for 24 h. For UV
irradiation, the culture medium was removed and the cells were
covered with PBS. Cells were irradiated at 10 mJ/cm2 using a
Bio-link Crosslinker (Vilber Lourmat, France) then further
incubated at 37uC.
Immunoprecipitation
Cell lysates were immunoprecipated with both antibodies (AB-a
and AB-b) as previously described [25]; however DNA-based
purification was omitted.
Mass Spectrometry and phosphopeptide enrichment
Protein bands were excised from a Coomassie-stained gel,
destained and subjected to trypsin digest as previously described
[25]. Following digestion, phosphopeptides were purified as
described [26] and then analysed on a Thermo Velos Orbitrap
mass spectrometer coupled to a Dionex Ulitmate 3000 HPLC
system. Peptides were loaded onto a pre-column (Dionex
300 mm65 mm, C18, 5 mm) and separated on a 12 cm6100 mm
column packed with ReproSil-Pur 120 C18-AQ 3 mm resin (Dr.
Maisch GmbH) running at 250 nl/min. Samples were loaded in
0.5% (v/v) formic acid in water and separated over a 35 min
linear gradient of 0% (v/v) acetonitrile to 32% (v/v) acetonitrile.
Table 2. Clinical and Pathological Characteristics of the
Singapore Cohort.
Number of patients 206
Median age (range) (years) 50 (24–85)
Ethnicity
Chinese [n (%)] 176 (85)
Malay 16 (8)
Indian 8 (4)
Other 6 (3)
Pathological stage at diagnosis [n (%)]
Stage 1 42 (20)
Stage 2 119 (58)
Stage 3 35 (17)
24 month survival (%)
Stage 1 100
Stage 2 96
Stage 3 93
Histologic type [n (%)]
Ductal 185 (89)
Lobular 14 (5)
Tubular 7 (3)
Histologic grade [n (%)]
Grade 1 42 (20)
Grade 2 82 (40)
Grade 3 82 (40)
Lymph node status [n (%)]
Negative 108 (52)
Positive 98 (48)
Estrogen Receptor status [n (%)]
Negative 24 (12)
Positive 182 (88)
Progesterone Receptor status [n (%)]
Negative 20 (10)
Positive 186 (90)
Subtype no data
doi:10.1371/journal.pone.0020603.t002
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over the next 5 min and then to 90% (v/v) over a one min period.
The column was re-equilibrated prior to each sample. The initial
MS scan (350–2000 m/z) was performed in the Orbitrap with the
resolution set to 60,000. Following this scan, MS/MS of up to the
top 20 peptides was performed in the linear ion trap with the
normalised collision energy set to 35. Data were searched using
Mascot 2.3.0 and the SWISS-PROT database (56.6) limited to
human (20413 sequences) with the precursor mass set to 10 ppm
and MS/MS tolerance at 0.6 Da. Modifications included
deamidation (N,Q), methionine sulphoxide and phosphorylation
(S,T,Y). All phosphopeptides were manually analysed for correct
site assignment.
Immunofluorescent cytochemistry
For slide preparation, medium was removed from wells, washed
with PBS, and fixed with paraformaldehyde (2% v/v). They were
then permeabilized with PBS/0.5% v/v Triton X-100 and after
further washing, incubated with primary antibodies (YB-1, 1:1000;
hnRNP A1, 1:1000) in antibody solution (2% w/v BSA, 0.1% w/v
NaN3, 0.2% w/v cold fish gelatin, in TBS/0.1% v/v Triton X-
100) and incubated for 1 h. Slides were then stained with Alexa-
Fluor 488 goat anti-rabbit secondary antibody (Invitrogen 1:2000)
in the presence or absence of the nuclear marker 49-6-Diamidino-
2-phenylindole (DAPI; Invitrogen). Cells were visualized with a
Leica Axioplan upright microscope equipped for epifluorescence
and photographed with a SPOT-RT Slider cooled CCD camera
(Diagnostic Instruments).
Confocal immunofluorescence microscopy
Formalin-fixed paraffin-embedded tumour sections were pro-
cessed as above and residual aldehydes quenched with 0.1 M
glycine in PBS. Following antigen retrieval, rabbit polyclonal
primary antibodies to epitopes a and c were used to label YB-1
and detected with an anti-rabbit IgG Alexa Fluor 488 secondary
antibody (Invitrogen, 1:2000). Labelling was visualised by confocal
Figure 2. Levels of YB-1 are increased in grade 3 breast tumours as detected by AB-a, but not other antibodies. IHC was carried out on
formalin-fixed paraffin-embedded breast tumours (n=90) from the New Zealand cohort using three antibodies targeting different epitopes (a–c) and
compared to adjacent normal tissue (insets). Staining patterns and levels of expression are shown for each antibody. Differences in staining intensity
as detected by AB-a were significant (p,0.02) whereas those detected by AB-c were not (p=0.06). Nuclear YB-1, as detected by AB-a was evident in
,3% of cases (arrowhead, upper middle panel). Scale bars 10 mm.
doi:10.1371/journal.pone.0020603.g002
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microscope. Multiple z-stacks were collected for each sample
(0.47 mm optical dissection).
SDS-PAGE and Immunoblotting
Cells were harvested as previously described [25] and the
protein content of each sample was determined by BCA protein
assay and standardized accordingly. Equal volumes of samples and
DSL loading buffer were denatured and loaded on a 10–12%
SDS–PAGE. Following electrophoresis, protein extracts were
transferred to PVDF membrane (Amersham). Immunoblotting
experiments were carried out with YB-1 antibodies as described
previously at a dilution of 1:1500 and incubated overnight at 4uC.
b-tubulin (E7, DSHB) was used as a loading control at a dilution of
1:20,000. Detection was carried out according to standard
procedures and bands visualized using the WesternBreeze
TM
chemiluminescent system (Invitrogen).
Nuclear Fractionation and Native Gel Electrophoresis
A549 cells were cultured as above and after harvesting were
fractionated into cytoplasmic and nuclear compartments as
previously described [25]. Blue native polyacrylamide gel
electrophoresis (BN-PAGE) was performed using the NativePA-
GE
TM Novex Bis-Tris system as outlined in the user manual
(Invitrogen). Immunoblotting was done as above. b-Tubulin
antibody (clone E7, Developmental Studies Hybridoma bank,
University of Iowa, USA, 1:2000) was used as a nuclear
fractionation marker.
Statistical Analysis
x
2-Test or Fisher9s Exact tests were used as appropriate. p values
#0.05 were considered statistically significant. Calculations were
performed using STATA Version 9.1 (StataCorp) or GraphPad
Prism Version 4.0 b software.
Results
Characterisation of antibodies
Antibodies to epitopes a and c were generated based on published
sequences [16,27], (also see methods), and the specificity of both
antibodies has been confirmed by mass spectrometry sequencing
[25]. Consistent with this, both antibodies detect a single protein
species of ,49 kDa on SDS-PAGE which is markedly diminished by
treatment with two distinct YB-1 specific siRNAs in four different cell
lines([25],A549andMCF-7;dataforothercelllinesnotshown).The
third antibody (epitope b, Abcamab12148) isused in apublic tumour
database (http://www.proteinatlas.org). This antibody detects two
protein species that migrate at ,49 kDa and ,37 kDa, the latter of
which was sequenced and identified as hnRNP A1 [25]. Following
knockdown of YB-1 (Figure S1) we observed that hnRNP A1 is
located in the nucleus whereas YB-1 is abundant in the cytoplasm.
However, hnRNP A1 is known to be present in both compartments
[28], making the immunostaining produced by the antibody difficult
to interpret. This cross-reactivity was discovered once the Dunedin
cohort had been analysed and our analyses found that AB-b did not
correlate with tumour grade or ER/PR status. Representative images
from this work on the Dunedin cohort are included alongside those
Figure 3. Both AB-a and AB-c detect increased levels of YB-1 in the larger Singapore cohort. TMAs with samples from 206 breast tumours
were stained with AB-a and AB-c and analysed for YB-1 intensity and location. The statistical analysis of this is shown for TMAs on the basis of grade
(upper panels) and ER/PR status (lower panels). The correlation of AB-a to tumor grade was highly significant, (x
2=35.95, p,0.005); that of AB-c was
less significant (x
2=8.623, p,0.02). The correlation of AB-a to ER/PR negativity was highly significant, (x
2=40.71, p,0.005); that of AB-c was less so
(x
2=28.17, p,0.015).
doi:10.1371/journal.pone.0020603.g003
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not discussed further, as it is not possible to reliably distinguish
between YB-1 and hnRNP A1.
YB-1 staining intensity correlates with tumour grade
To determine whether all YB-1 antibodies showed the same
staining pattern and were similarly associated with prognosis, we
examined two cohorts of breast tumours comprising different
grades to evaluate YB-1 abundance in relation to immediately
adjacent normal tissue. One cohort (n=90) is from New Zealand
(clinical details in Table 1) and the other, larger cohort (n=206)
involving a different racial mix, is from Singapore (clinical details
in Table 2). Grade 2 tumours were excluded from both cohorts as
recent gene expression profiling has revealed that these tumours
do not have a distinct genetic profile, but have comparable genetic
profiles and clinical outcomes to either grade 1 or 3 tumours [29].
Examples of IHC results from the NZ cohort are shown in
Figure 2. The intensity of YB-1 as detected with AB-a (top panels)
is clearly higher in the grade 3 tumours compared to grade 1
tumours when normalized to the adjacent normal tissue (insets).
We did not find any instances of negative (zero) staining. Further
examination showed considerable heterogeneity in staining
intensity in both grade 1 and grade 3 tumours compared to
adjacent normal tissue. However, quantitative analysis of these
data revealed that generally a greater proportion of grade 3
tumours had higher levels of YB-1 than grade 1 tumours (Figure 2,
p,0.02; Fisher’s exact). A similar staining pattern and trend of in-
creased levels of YB-1 in grade 3 tumours was observed with AB-c
(Figure 2, bottom panels), but did not reach significance (Figure 2,
p=0.06; Fisher’s exact).
To determinewhether differencesinYB-1 antibody stainingwere
also observed in the larger Singapore breast cancer cohort, a similar
YB-1 abundance analysis by tumour grade was carried out with AB-
a and AB-c (Figure 3, upper panels). In this case YB-1 abundance
detectable with AB-a showed a high correlation with tumour grade
(x
2=35.95, p,0.005); similarly, YB-1 detectable with AB-c showed
a significant trend with respect to tumour grade, although it was 2
orders of magnitude less significant (x
2=8.623, p,0.02).
Figure 4. Levels of YB-1 are increased in ER/PR negative breast tumours as detected by AB-a, but not other antibodies. IHC was
carried out on formalin-fixed paraffin-embedded tumours (n=90) from the New Zealand cohort using three antibodies targeting different epitopes
(a–c). Staining patterns and levels of expression are shown for representative sections for each antibody: ER/PR positive tumours are represented in
the left hand column; ER/PR negative tumours in the central column. Differences in staining intensity as detected by AB-a were significant (p,0.007)
whereas those detected by AB-c were not (p=0.08). Scale bars 10 mm.
doi:10.1371/journal.pone.0020603.g004
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Gene expression analysis studies [30,31] have been used to
subtype breast tumours. Of these, tumours that are ER/PR
negative include the more aggressive basal-like and ERBB2
(HER2)
+ tumours. We therefore investigated whether the
detectable levels of YB-1 were significantly different in ER/PR
negative tumours with each of the YB-1 antibodies. In the NZ
cohort, as for tumour grade, we found a greater proportion of ER/
PR negative tumours had the strongest YB-1 staining as detected
by AB-a, which reached a high level of significance over the cohort
(Figure 4, p,0.007; Fisher’s exact). The staining intensity with AB-
c did not reach statistical significance (Figure 4, p=0.08; Fisher’s
exact). When the Singapore cohort was examined with AB-a and
AB-c (Figure 3, lower panels), both showed more intense staining
in the ER/PR negative group, but as was found for tumour grade,
the relationship was much stronger with AB-a (x
2=40.71,
p,0.005) than with AB-c (x
2=28.17, p,0.015).
Heterogeneous YB-1 expression in normal breast tissue
with AB-a and AB-c
Given the heterogeneity of YB-1 staining intensity observed in
the tumours and adjacent normal tissue, we investigated non-
pathological breast tissue from reduction mammoplasties to see if a
similar pattern was evident. Staining with both AB-a (Figure 5)
and AB-c (data not shown) showed that YB-1 was present in all of
the reduction mammoplasties analysed. This staining was
heterogeneous and was particularly intense in cells with columnar
alterations of lobules with prominent apical snouts and secretions
(CAPSS; arrowheads in Figure 5, ii and iv). Thus the heterogeneity
of YB-1 expression is a normal feature of breast tissue. Several
normal and cancer cell lines were also examined in which we
found YB-1 to be expressed in all cases (Figure S2). Although the
levels varied there was no marked difference between normal
breast epithelial and breast cancer cell lines.
Nuclear YB-1 is detected with AB-a in breast cancer tissue
but not with AB-c
During the above experiments subcellular localization of YB-1
was also determined. In almost every case YB-1 was found to be
cytoplasmic with antibodies AB-a and AB-c, irrespective of which
tumour cohort was examined. We found only 3 tumour sections
where nuclear YB-1 was apparent with AB-a (eg, see arrowhead
Figure 2, grade 3 tumour, AB-a). Because conventional IHC is
carried out on relatively thick (5 mm) sections we wanted to
determine whether this apparent nuclear staining detected with
AB-a was real, or due to the plane of section. We therefore imaged
the tumour samples with confocal immunofluorescence microsco-
py using a 0.47 mm optical slice. Results show limited punctate
staining in the nucleus with AB-a (Figure 6, upper panel) that is not
discernible using conventional microscopy. However, increased
perinuclear staining is evident with this antibody (Figure 6, upper
panel) so it is possible that such staining could be misinterpreted as
nuclear staining at the light microscopy level. Cytoplasmic YB-1 as
detected with AB-c was less intense, and there was no evidence of
nuclear staining (Figure 6, lower panel). Given the demonstrated
specificity of the antibodies, these results suggest that AB-a is
detecting a subset of YB-1 that is present, albeit at relatively low
levels, within the nucleus that is not detected by AB-c.
Stress-induced nuclear translocation of YB-1 is detected
only with antibody AB-a
As indicated above, nuclear YB-1 was rarely detected in
tumours and only with AB-a. A commonly reported feature of YB-
1 is its propensity to translocate to the nucleus of cells after being
subjected to treatment with different stressors [7,9,27]. To
investigate whether the two antibodies can bind to nuclear YB-
1, we increased the number of A549 cells with nuclear-localised
YB-1 by treating with UV radiation and cisplatin. Results show
that nuclear YB-1 was detectable with AB-a after treatment with
UV and cisplatin (Figure 7A, arrowheads), but no nuclear YB-1
staining was observed in untreated control cells. In contrast, only
cytoplasmic YB-1 staining was detected with AB-c irrespective of
treatment. Similar results were obtained with MCF-7 breast
cancer cells (Figure S3). We next used confocal immunofluores-
cence microscopy to discern whether this apparent nuclear YB-1
detected with AB-a was indeed nuclear or perinuclear as seen
above. Using A549 cells, and a second breast cancer cell line,
T47D, antibody AB-a showed clear punctuate and disperse
nuclear localization (Figure 7B, arrowheads) and increased
cytoplasmic intensity after exposure to UV radiation. However,
no nuclear YB-1 was observed with AB-c, although the
Figure 5. Heterogeneous expression of YB-1 in normal breast tissue. Cytoplasmic and perinuclear YB-1 is detected in both normal lobular
(i, iii and v) and ductal (ii, iv and vi) tissue. Insets show staining at a higher magnification. Arrowheads (panels ii and iv) depict high levels of YB-1 in
columnar alterations with prominent apical snouts and secretions (CAPSS). Scale bars 20 mm.
doi:10.1371/journal.pone.0020603.g005
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were also increased after stress treatment. Thus, as for the tumour
IHC analysis, each YB-1 antibody displays a distinctive staining
pattern that could lead to different interpretation. That is, based
on AB-c staining, one could conclude that there is no stress
induced nuclear translocation of YB-1, while the exact opposite
conclusion could be derived from AB-a staining.
Phosphorylation of epitope c does not prevent
immunoreactivity of AB-c
One possible explanation as to why AB-c does not detect
nuclear YB-1 and exhibits reduced sensitivity as a prognostic tool
is that the epitope for AB-c is masked by post-translational
modification(s). Phosphorylation of serine residues 313 and 314
have been reported [32,33,34,35]. These are situated within, or
directly adjacent to, epitope c (Figure 1) and where present may
abrogate binding of AB-c but not AB-a. To test this, A549 cells
that had been treated with cisplatin were immunoprecipitated with
either AB-a or AB-c (Figure 8A). Phosphopeptides generated from
YB-1 tryptic digests were then subjected to LC/MS/MS.
Phosphorylation of S314, but not S313, was detected in both
samples derived from immunoprecipitation with AB-a and AB-c
respectively, suggesting that phosphorylation of this residue does
not interfere with the interaction of AB-c with YB-1 (Figure 8B).
Thus, it seems unlikely that phosphorylation in the region of the
epitope recognised by AB-c could be a contributing factor in the
reduced sensitivity observed in the breast tumours by AB-c.
Furthermore, western blotting of cell-line lysates with both AB-a
and AB-c, as exemplified by Figure 9A, revealed immunoreactivity
in both cytoplasmic and nuclear fractions. This further reinforces
that phosphorylation, or any denaturation-resistant post-transla-
tional modification, in the region of either epitope, does not
contribute to the observed differential immunoreactivity of AB-a
and AB-c in the tumour samples.
AB-a and AB-c detect distinct YB-1 protein complexes
An alternative explanation as to why AB-c is not detecting
nuclear YB-1 could be that epitope c is masked by proteins
interacting with YB-1. In order to investigate this possibility,
nuclear and cytoplasmic fractions from A549 cells were separated
by native electrophoresis and immunoblotted with antibodies AB-a
and AB-c. Both antibodies detected YB-1 in multiple high
molecular weight complexes (Figure 9B). While AB-a and AB-c
detected YB-1 complexes of <720 kDa (band 1) in both nuclear
and cytoplasmic fractions, the nuclear complexes detected by AB-a
were more discrete in comparison to those detected by AB-c.
These data suggest that AB-a detects a sub-population of the YB-1
containing complexes that migrate at that mass. AB-c also detected
two other YB-1 complexes of <300 kDa (band 2) and <100 kDa
(band 4) in the cytoplasmic fraction that are both absent from the
nuclear fraction. Band 4 corresponds to monomeric YB-1 and is
weakly detected by AB-a, as denatured YB-1 runs with the same
mobility (data not shown). AB-a also detected a YB-1 complex of
<250 kDa (band 3) in the nuclear and cytoplasmic fractions. That
band 3 is detected in the nucleus by AB-a but not by AB-c would
suggest that the nuclear staining observed in cells by immunoflu-
orescence (and in the tumours) is associated with this complex.
Presumably the band 1 complex (common to both antibodies) is
masked under immunostaining conditions, at least in the nucleus.
These findings are consistent with the interpretation that YB-1
forms discrete functional complexes and that epitope c of YB1 is
not available for binding by AB-c in a subset of these functional
complexes.
Discussion
We set out to determine whether IHC analysis of breast
tumours using antibodies generated to different YB-1 epitopes
might lead to different conclusions about the value of YB-1 as a
prognostic tool. Using two antibodies, we investigated whether
there are differences in the subcellular localisation of YB-1 and
whether its abundance increases with tumour progression. Two
different tumour cohorts were used in this study, one from NZ and
one from Singapore. With the N-terminal antibody (AB-a), we
found that the staining intensity of cytoplasmic YB-1, although
variable, tended to be highest in grade 3 tumours and in the more
aggressive ER/PR negative tumours. These findings confirm
previous reports, carried out with an antibody generated to the
same N-terminal epitope [11,19,21]. The increase in staining was
most marked in the cytoplasmic region directly adjacent to the
nucleus (perinuclear), possibly due to an increase in YB-1 binding
Figure 6. Ab-a but not Ab-c detects both increased perinuclear
cytoplasmic staining and punctate nuclear staining of YB-1 in
grade 3 breast tumours. YB-1 in breast tumour sections were
labelled with either Ab-a or Ab-c and visualized with Alexa Fluor 488
secondary antibody prior to confocal analysis. Representative mid z-
stack sections are shown for each of the antibodies. Arrowheads show
punctate nuclear staining not detectable by light microscopy. Scale bars
5.0 mm.
doi:10.1371/journal.pone.0020603.g006
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[36]. However, unlike reports using an antibody generated against
an N-terminal epitope [11,19,21], we detected few instances
(,3%) of nuclear staining in any tumour. Further investigation by
confocal immunofluorescence microscopy showed that AB-a
detected punctate nuclear staining in grade 3 tumours which is
not discernable by light microscopy and therefore previous reports
may have interpreted the increased perinuclear intensity as
nuclear staining due to the plane of section.
Cytoplasmic YB-1 detected with AB-c was also highest in grade
3 and ER/PR negative tumours. It did not reach statistical
significance in the smaller NZ cohort but did show a significant
difference in the Singapore cohort; however, this was of lesser
magnitude than that found with AB-a. As with AB-a, the increase
in cytoplasmic staining was most notable in the perinuclear region.
These findings are in agreement with elevated YB-1 levels,
detected by an antibody generated to the same C-terminal peptide
sequence, previously reported in breast cancer [22,24], non-small
Figure 7. Stress induced nuclear translocation of YB-1 is detectable with antibody AB-a. A, Immunofluorescent analysis of YB-1 expression
in A549 cells after ultraviolet (UV) light or cisplatin (Cis) treatment using antibodies AB-a and AB-c. Cell nuclei are counterstained with DAPI that
becomes translucent following YB-1 nuclear localization (merged image – see arrowheads). B, confocal immunofluorescent labeling of YB-1 levels
using AB-a and AB-c in A549 and T47D cells after UV exposure. Arrowheads indicate nuclear YB-1. Ctrl=untreated controls.
doi:10.1371/journal.pone.0020603.g007
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these reports, our analysis with this antibody using confocal
immunofluorescence microscopy did not find any evidence of
nuclear YB-1 staining.
Notably, we found cytoplasmic YB-1 in all normal breast tissue,
particularly in luminal cells with CAPSS. This is the first report
that YB-1 is elevated in cells with CAPSS lesions, which have
previously been reported to be ER/PR negative [37]. The
increased level of YB-1 in these cells is consistent with our findings
in tumour tissue where YB-1 is elevated in ER/PR negative
tumours. The presence of YB-1 in normal breast tissue is in
contrast to previous findings [11,21].
The differences observed in immunoreactivity of AB-a and AB-c
in tissues was examined further in tissue culture after treating cells
with DNA damaging agents to induce nuclear translocation of YB-
1. Again, we found that stress treatment increased YB-1 levels in
the cytoplasm as detected with both antibodies but nuclear YB-1
was only detected with AB-a. Thus, AB-a detected a sub-
population of YB-1 molecules that AB-c did not.
To explain these differences a number of possibilities were
considered. The most obvious was that the antibodies have different
binding affinities to YB-1. However, the Kd of each antibody, as
measured by immunoprecipitation, was found to be approximately
5 nM (data not shown), making this explanation unlikely. It could
be that AB-c is unable to access epitope c when YB-1 is located in
the nucleus due to fixation procedures, as suggested previously
[22,24]. However, this also seems unlikely, as this antibody did not
detect nuclear YB-1 with immunocytochemistry on cultured cells,
where fixation and tissue thickness is not an issue. Another
possibility is that epitope c is obscured by post-translational
modifications that are important when YB-1 is in its native
conformation. Phosphoserine 314, adjacent to epitope c, was
identified in both AB-c and AB-a immunoprecipitated YB-1.
Therefore, phosphorylation of YB-1 on serine 314 seems to be an
unlikely explanation. Nuclear YB-1 can be phosphorylated at serine
102 [38,39] and it has been proposed that this phosphorylation is
required for stress-induced nuclear translocation of YB-1. It is
therefore possible that phosphorylation at serine 102 induces a
conformational change to prevent the binding of AB-c, however,
serine 102 was not detected with either antibody in these
experiments.
Another possible explanation for the apparent differences in
epitope availability may be due to steric inhibition caused by
protein-protein interactions. Protein lysates separated in the
absence of reducing or denaturing agents to preserve protein:pro-
tein moieties, suggest that antibodies AB-a and AB-c differ in their
ability to detect specific YB-1 containing protein complexes. The
detection of YB-1 by AB-c in the nuclear fraction is contrary to our
findings that AB-c is unable to detect nuclear YB-1 in either
paraffin-embedded tissue or in cell culture. A reason for this
discrepancy may be that YB-1 binds RNA to form homodimeric
YB-1:RNA complexes [40]. The formation of these YB-1:RNA
complexes involves the CSD and the C-terminal region [41] and
may render epitope c inaccessible in YB-1 molecules that are
integrated into the YB-1:RNA complexes. The role of the C-
terminal region in forming these YB-1:RNA multimers increases
Figure 8. YB-1 Phosphoserine 314 is detected with both AB-a and AB-c. A, Coomassie-stained SDS–PAGE analysis of A549 cell extracts
showing that YB-1 co-immunoprecipitates with either AB-a and AB-b. The bands contained within the red box were independently excised and
subjected to LC/MS/MS analysis. B, A representative MS/MS spectra of the peptide AADPPAENSpSAPEAEQGGAE is shown. The observed y- and b-ions
and the sequence of the peptide with the corresponding ions is shown. The data indicate phosphorylation of serine-314 (red star) and not serine-313.
doi:10.1371/journal.pone.0020603.g008
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correlated elevated YB-1 levels with grade and negative ER/PR
status. Therefore, the increased sensitivity of AB-a relative to AB-c
may be due to a reduction in the availability of epitope c caused by
the effects of increasing YB-1:RNA ratio on YB-1:RNA multimer
formation.
The data presented highlight the need for standardized
antibodies for analysis of clinical material if YB-1 is to gain
acceptance as a reliable prognostic marker, as has been done for
the prognostic determination of the ER and HER2 immunostain-
ing on breast cancers [42,43]. Our results suggest that the staining
pattern depends on epitope accessibility to the antibody and that
apparent absolute levels are not in fact absolute; rather, they are
levels of YB-1 available for detection, which in turn is dependent
on the nature of the complex containing YB-1. From our data it
would appear that antibodies to the extreme N-terminus of YB-1
seem to be the most sensitive because this region does not interact
with other proteins to preclude recognition of its epitope, as
appears to occur with AB-c. Validated monoclonal antibodies to
this region could ultimately be the best way of ensuring
reproducibility, thereby realising the potential of YB-1 as a
reliable marker of cancer progression and prognosis.
Supporting Information
Figure S1 siRNA knockdown of YB-1 shows that cytoplasmic
staining of YB-1 by AB-b is predominantly YB-1, whereas nuclear
staining is hnRNP A1. A, Immunofluorescent staining with AB-b
following knockdown with either siYB-1 or a non-targeting siRNA
(NT) in both untreated (-), ultra violet treated (UV) and cisplatin-
treated (Cis) cells. Cytoplasmic staining is absent following
knockdown with siYB-1. B, Western blot showing that YB-1, as
detected by AB-b (50 kDa), is reduced following knockdown with
siYB-1, hnRNP A1, as detected by AB-b (37 kDa), is reduced
following knockdown with si hnRNP A1.
(TIF)
Figure S2 YB-1 is present in both immortalised and non-
immortalised cell lines. The amount of YB-1 in a panel of
Figure 9. Different YB-1 antibodies detect different YB-1 protein complexes. A, nuclear and cytoplasmic fractions of A549 cells were
subjected to SDS-PAGE and immunoblotting with antibodies AB-a and AB-c. b-tubulin, exclusively cytoplasmic, was used as a control to confirm that
the nuclear fraction did not contain any cytoplasm. B, A549 fractions from A were separated by BN-PAGE, immunoblotted and incubated with YB-1
antibodies AB-a and AB-c.
doi:10.1371/journal.pone.0020603.g009
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Western blotting using YB-1 antibody AB-a. An antibody to b-
tubulin (DSHB) was used as a loading control.
(TIF)
Figure S3 Stress induced nuclear translocation of YB-1 in MCF-
7 cells is detectable with antibody AB-a but not AB-c.
Immunofluorescent analysis of YB-1 expression in MCF-7 cells
after ultraviolet (UV) light or cisplatin (Cis) treatment using
antibodies AB-a and AB-c. Cell nuclei are counterstained with
DAPI that becomes translucent (arrowheads) following YB-1
nuclear localization. Ctrl = untreated controls.
(TIF)
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